"the date on which the Company publishes the data readouts of its Phase 1b trials of FAP-Dox (AVA6000) in triple negative breast cancer and (ii) 30 June 2026"
As we know 1b isn't just breast cancer. June RNS was a new response in SGC.
I've drawn some charts and mind maps and I would surmise that we are going to get an RNS with a response to TNBC and partnership will follow that will more than cover the remaining 13 mil loan.